Bristol-Myers Squibb’s long-serving chief executive Giovanni Caforio has said he will retire on 1st November after almost eight years in the role and more than two decades
March wasn’t the busiest month for big pharma shakeups, especially compared to the start of the year, but there was plenty of hustle and bustle at smaller pharma and biotech firms.
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZe
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.